Researchers from IDIBELL and ICO have participated in a multicenter study, published in Nature Genetics, which shows that the implantation of human tumors in nude mice does not lead to additional DNA changes.
Aptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer.
The study lead by Columbia University, in collaboration with IDIBELL and ICO, analysed thousands of tumours. They found that the key genetic programs necessary for the survival of cancer cells are controlled by only 24 modules, each one comprising only a handful of Master Regulators proteins working in concert.
